219 related articles for article (PubMed ID: 17169626)
1. Identification of and management approaches for the high-risk patient.
Bhatt DL
Am J Cardiol; 2006 Dec; 98(12A):22Q-29Q. PubMed ID: 17169626
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
3. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
5. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
6. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
[TBL] [Abstract][Full Text] [Related]
7. Aspirin resistance or variable response or both?
Cheng X; Chen WH; Simon DI
Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
[TBL] [Abstract][Full Text] [Related]
8. Combination antiplatelet agents in ischemic cerebrovascular disease.
Moussouttas M; Papamitsakis N
Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
[TBL] [Abstract][Full Text] [Related]
9. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
10. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Collet JP; Montalescot G
Int J Cardiol; 2009 Mar; 133(1):8-17. PubMed ID: 19187982
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
[No Abstract] [Full Text] [Related]
12. Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
Bakhru MR; Bhatt DL
Cleve Clin J Med; 2008 Apr; 75(4):289-95. PubMed ID: 18491435
[TBL] [Abstract][Full Text] [Related]
13. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Booth J; Topol EJ;
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169314
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Spinler SA
Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
[TBL] [Abstract][Full Text] [Related]
16. Facts and controversies of aspirin and clopidogrel therapy.
Faxon DP; Freedman JE
Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in populations at high risk of atherothrombosis.
Faxon DP; Nesto RW
J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
[TBL] [Abstract][Full Text] [Related]
18. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
Fisher M
Arch Neurol; 2006 Jan; 63(1):20-4. PubMed ID: 16401733
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
Chen J; Shi C; Mahoney EM; Dunn ES; Rinfret S; Caro JJ; O'Brien J; El-Hadi W; Bhatt DL; Topol EJ; Cohen DJ
Can J Cardiol; 2011; 27(2):222-31. PubMed ID: 21459271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
